LivaNova (NASDAQ:LIVN) Stock Price Expected to Rise, Mizuho Analyst Says

LivaNova (NASDAQ:LIVN) had its price target upped by stock analysts at Mizuho from $85.00 to $90.00 in a research report issued on Thursday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Mizuho’s target price would suggest a potential upside of 35.83% from the company’s current price.

A number of other research firms have also recently issued reports on LIVN. The Goldman Sachs Group reissued a “neutral” rating and set a $66.00 target price on shares of LivaNova in a research note on Friday, January 9th. Piper Sandler reissued an “overweight” rating and set a $85.00 target price on shares of LivaNova in a research note on Thursday, February 19th. Barclays set a $76.00 target price on LivaNova in a research note on Thursday. Needham & Company LLC increased their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, Stifel Nicolaus set a $80.00 target price on LivaNova in a research note on Wednesday, February 25th. Seven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $77.22.

LivaNova Stock Performance

Shares of LIVN stock opened at $66.26 on Thursday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.36 and a quick ratio of 1.16. The stock has a market cap of $3.64 billion, a PE ratio of -14.86 and a beta of 0.82. The stock has a 50-day moving average of $63.97 and a 200-day moving average of $62.03. LivaNova has a one year low of $39.36 and a one year high of $71.92.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a positive return on equity of 16.54% and a negative net margin of 17.46%.The company had revenue of $362.30 million during the quarter, compared to analysts’ expectations of $346.05 million. During the same period in the prior year, the business posted $0.88 EPS. LivaNova’s revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, sell-side analysts expect that LivaNova will post 3.66 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently bought and sold shares of LIVN. Hantz Financial Services Inc. boosted its position in LivaNova by 159.9% during the 4th quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after acquiring an additional 267 shares during the last quarter. State of Wyoming acquired a new position in LivaNova during the 2nd quarter worth approximately $31,000. EverSource Wealth Advisors LLC boosted its position in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after acquiring an additional 639 shares during the last quarter. Quarry LP acquired a new position in LivaNova during the 3rd quarter worth approximately $36,000. Finally, UMB Bank n.a. boosted its position in LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after acquiring an additional 306 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q1 beat — LivaNova reported $0.98 EPS vs. consensus $0.85 and revenue of $362.3M (about +14% YoY), clear upside to estimates. LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Raised FY26 guidance — company lifted full‑year adjusted diluted EPS range to $4.20–$4.30 and raised revenue guidance to roughly $1.4–$1.5 billion, providing an upside EPS bias versus prior consensus. LivaNova Reports First-Quarter 2026 Results; Raises Guidance
• Positive Sentiment: Sector tailwinds — coverage highlights improving reimbursement dynamics that could support procedure volumes and longer‑term revenue growth. LivaNova earnings ahead as reimbursement tailwinds build
• Neutral Sentiment: Full Q1 transcript and slide deck available — investors can review management commentary and the conference call for detail on dynamics behind the beat and guidance. LivaNova (LIVN) Q1 2026 Earnings Transcript
• Negative Sentiment: Mixed market reaction — some reports noted shares briefly slipped in response to what some investors called “cautious” elements of the outlook (revenue range at the low end of expectations and conservative commentary), creating short‑term volatility. LivaNova beats estimates but shares fall 2% on guidance concerns

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.